CA2729868C - Anti- p2x7 peptides and epitopes - Google Patents

Anti- p2x7 peptides and epitopes Download PDF

Info

Publication number
CA2729868C
CA2729868C CA2729868A CA2729868A CA2729868C CA 2729868 C CA2729868 C CA 2729868C CA 2729868 A CA2729868 A CA 2729868A CA 2729868 A CA2729868 A CA 2729868A CA 2729868 C CA2729868 C CA 2729868C
Authority
CA
Canada
Prior art keywords
antibody
receptor
peptide
antibodies
functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2729868A
Other languages
English (en)
French (fr)
Other versions
CA2729868A1 (en
Inventor
Julian Alexander Barden
Angus Gidley-Baird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioceptre (aust) Pty Ltd
Original Assignee
Bioceptre (aust) Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903451A external-priority patent/AU2008903451A0/en
Application filed by Bioceptre (aust) Pty Ltd filed Critical Bioceptre (aust) Pty Ltd
Publication of CA2729868A1 publication Critical patent/CA2729868A1/en
Application granted granted Critical
Publication of CA2729868C publication Critical patent/CA2729868C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2729868A 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes Active CA2729868C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
AU2008903451 2008-07-04
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Publications (2)

Publication Number Publication Date
CA2729868A1 CA2729868A1 (en) 2010-01-07
CA2729868C true CA2729868C (en) 2018-07-10

Family

ID=41465424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2729868A Active CA2729868C (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Country Status (12)

Country Link
US (3) US8597643B2 (https=)
EP (1) EP2318438B1 (https=)
JP (2) JP5701752B2 (https=)
KR (1) KR101701300B1 (https=)
CN (1) CN102143978B (https=)
AU (1) AU2009266430B2 (https=)
BR (1) BRPI0915367B8 (https=)
CA (1) CA2729868C (https=)
ES (1) ES2610225T3 (https=)
IL (2) IL210220A (https=)
NZ (1) NZ590146A (https=)
WO (1) WO2010000041A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
US20180037650A1 (en) * 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
CN112166193A (zh) 2018-05-21 2021-01-01 生物权威（英国）有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
BR112023020659A2 (pt) * 2021-04-08 2023-12-05 Biosceptre Aust Pty Ltd Métodos para controlar a atividade de célula imune
JP2025531675A (ja) * 2022-09-14 2025-09-25 バイオセプター （オースト） プロプライエタリー・リミテッド 操作された免疫細胞の富化
CN120166997A (zh) * 2022-09-14 2025-06-17 生物权威(澳大利亚)有限责任公司 检测免疫细胞的方法
CN120187461A (zh) * 2022-09-14 2025-06-20 生物权威(澳大利亚)有限责任公司 免疫细胞的体内检测

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
AU2566595A (en) 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
WO1997006256A2 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP2001521372A (ja) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ヒトＰ２ｘ４レセプタースプライス−変異体
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
WO2002047306A1 (en) * 2000-12-06 2002-06-13 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
CN100497386C (zh) 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
EP1469072B1 (en) 2003-04-17 2007-08-29 Affectis Pharmaceuticals AG Means and methods for diagnosing and treating affective disorders
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.

Also Published As

Publication number Publication date
US8597643B2 (en) 2013-12-03
US20160199442A1 (en) 2016-07-14
AU2009266430A1 (en) 2010-01-07
BRPI0915367B1 (pt) 2020-10-13
CA2729868A1 (en) 2010-01-07
US10238716B2 (en) 2019-03-26
US20140135475A1 (en) 2014-05-15
WO2010000041A1 (en) 2010-01-07
BRPI0915367A2 (pt) 2015-11-03
NZ590146A (en) 2012-09-28
EP2318438A1 (en) 2011-05-11
AU2009266430B2 (en) 2014-08-14
IL210220A (en) 2016-04-21
JP2015038144A (ja) 2015-02-26
CN102143978A (zh) 2011-08-03
KR20110031222A (ko) 2011-03-24
KR101701300B1 (ko) 2017-02-01
US9328155B2 (en) 2016-05-03
US20110110959A1 (en) 2011-05-12
EP2318438B1 (en) 2016-11-02
JP5701752B2 (ja) 2015-04-15
JP2011526249A (ja) 2011-10-06
IL232394A0 (en) 2014-06-30
AU2009266430A8 (en) 2011-03-10
ES2610225T3 (es) 2017-04-26
IL232394A (en) 2016-04-21
EP2318438A4 (en) 2012-11-21
CN102143978B (zh) 2015-02-18
IL210220A0 (en) 2011-03-31
BRPI0915367B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CA2729868C (en) Anti- p2x7 peptides and epitopes
JP6417016B2 (ja) 抗ｐ２ｘ７受容体抗体およびその断片
US8067550B2 (en) Hybridomas producing antibodies against non functional P2X7 receptor
ES2811274T3 (es) Anticuerpos monoclonales humanizados y quiméricos para CD99
EP2201026B1 (en) Novel p2x7 epitopes
CN114401744B (zh) 用于治疗癌症的抗cd33抗体
WO2007110648A1 (en) Agonist antibodies against tshr
CN114341176A (zh) Cd19抗体及其使用方法
KR20230147624A (ko) 면역조절 항체 및 이의 용도
US20150125385A1 (en) Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
US9840560B2 (en) Monoclonal antibodies to EGFR, and uses therefor
TW202311293A (zh) 免疫療法之組合及其用途
HK1152046B (en) Anti-p2x7 peptides and epitopes
HK1152046A (en) Anti-p2x7 peptides and epitopes
CN117062835A (zh) 免疫调节性抗体及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140630

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250626

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250626